Key result
An integrated approach using clinical risk stratification, high-sensitivity cardiac biomarkers, and non-invasive testing is required to safely assess patients with possible cardiac chest pain.
An integrated clinical approach using risk stratification, sensitive biomarkers, and non-invasive testing is recommended for safely and effectively evaluating patients with possible cardiac chest pain.
Answers are grounded in this paper and cite their sources.
May guide current chest pain pathways; leaves open the need for prospective validation.
Chest pain is a common reason for presentation in hospital emergency departments and general practice. Some patients presenting with chest pain to emergency departments and, to a lesser extent, general practice will be found to have a life-threatening cause, but most will not. The challenge is to identify those who do in a safe, timely and cost-effective manner. An acute coronary syndrome cannot be excluded on clinical grounds alone. In patients with ongoing symptoms of chest pain, without an obvious other cause, ST-segment-elevation myocardial infarction should be excluded with a 12-lead electrocardiogram at the first available opportunity. Significant recent advances in the clinical approach to patients with acute chest pain, including better understanding of risk stratification, increasingly sensitive cardiac biomarkers and new non-invasive tests for coronary disease, can help clinicians minimise the risk of unexpected short-term adverse cardiac events. An approach that integrates these advances is needed to deliver the best outcomes for patients with chest pain. All hospital emergency departments should adopt such a strategic approach, and general practitioners should be aware of when and how to access these facilities.
No takes yet. Share an insight, caveat, or question.
Parsonage et al. (2013) conducted a review in Cardiac chest pain. Chest pain assessment strategies was evaluated. An integrated approach using clinical risk stratification, high-sensitivity cardiac biomarkers, and non-invasive testing is required to safely assess patients with possible cardiac chest pain.
Synapse has enriched 10 related papers. Consider them for comparative context: